TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01751997
Drug: Transplants from family-mismatched/haploidentical donors
Approvals — FDA: no, EMA: no, PMDA: no
Description: * Reduced-intensity conditioning~  1. Total body irradiation; 200 cGy, every 12 hours, 4 doses, days -9 to -8 (total 800 cGy)~ 2. Fludarabine; 30 mg/m\^2/day, IV for 1 hour, days -7 to -3 (total 150 mg/m\^2)~ 3. Busulfex; 3.2 mg/kg/day, IV for 3 hours, days -6 to -5 (total 6.4 mg/kg)~ 4. ATG; 1.25 mg/kg/day, IV for 6 hours, days -4 to -1 (total 5.0 mg/kg)~* GVHD prophylaxis~  1. Tacrolimus; 0.03 mg/kg/day, IV for 24 hours from day -1 (0.12 mg/kg/day, PO, if tolerable)~ 2. Methotrexate; 5 mg/m\^2/day, IV push, days +1, +3, +6, +11
Study: NCT01665976
Drug: RO4917838
Approvals — FDA: no, EMA: no, PMDA: no
Description: film coated tablet, single dose
Study: NCT01665976
Drug: RO4917838
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral suspension, single dose
Study: NCT04227093
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo tablets taken twice daily.
Study: NCT02697058
Drug: 5-FU/calcium levofolinate
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-FU/calcium levofolinate alone
Study: NCT00133185
Drug: telmisartan 40 mg/hydrochlorothiazide 12.5 mg
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00133185
Drug: losartan 50 mg/hydrochlorothiazide 12.5 mg
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00797706
Drug: CHRONSEAL
Normalized name: COLOSTOMY SYSTEM,CONSEAL COLOPLAST #1201
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cream (1.4/2.8 g depending on ulcer size) topical administration, every 2nd day at 3 occasions
Study: NCT00823979
Drug: UK-453,061 Dose 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: UK 453,061 750 mg QD + one optimized NRTI + darunavir/ritonavir.
Study: NCT00823979
Drug: UK-453,061 Dose 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: UK 453,061 1000 mg QD + one optimized NRTI + darunavir/ritonavir.
Study: NCT03771885
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Film-coated Tablet
Study: NCT04461756
Drug: PPP001
Approvals — FDA: no, EMA: no, PMDA: no
Description: inhalation (vape)
Study: NCT00396305
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sterile phosphate buffered saline solution.
Study: NCT00431795
Drug: Pegylated liposomal doxorubicin (Caelyx)
Normalized name: doxorubicin hydrochloride liposome Injection [Caelyx]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pegylated liposomal Doxorubicin (Caelyx) at the dose of 50mg/m\^2 IV every 4 weeks for 6 consecutive cycles
Study: NCT00475813
Drug: FLUTIFORM® (Formoterol fumarate / Fluticasone propionate)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02784704
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04637425
Drug: Ismigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual tablets containing 7 mg of bacterial lysate from the following bacteria: Staphylococcus aureus, Haemophilus influenzae serotype B, Klebsiella pneumoniae, Klebsiella ozaenae, Neiserria catarrhalis, Streptococcus viridans, Streptococcus pyogenes, Streptococcus pneumoniae (6 strains: TY1/EQ11, TY2/EQ22, TY3/EQ14, TY5/EQ15, TY8/EQ23, TY47/EQ24) - sublingual use 1 tablet per day over 10 days for 3 successive months.
Study: NCT04637425
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matched tablets without any active substance.
Study: NCT01336140
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching 0.9 Normal Saline (sterile salt water)administered intravenously.
Study: NCT02884128
Drug: LV
Normalized name: VALVE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-FU/LV were started after the end of PEP02 infusion on Day 1 and also on Day 8. Treatment repeated every 3 weeks and it was regarded as one cycle of treatment.
Study: NCT00660179
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo, once daily
Study: NCT03080051
Drug: [18F]MNI-952
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will undergo PET imaging using \[18F\]MNI-952, a PET radioligand for imaging tau.
Study: NCT00354952
Drug: Macrolides (azithromycin or clarithromycin)
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT03783299
Drug: Artemether-lumefantrine
Normalized name: artemether-lumefantrine
Approvals — FDA: no, EMA: no, PMDA: no
Description: If found positive by standard RDT or HS-RDT, treatment will be administered, and women of reproductive age will be assessed as outlined in the protocol. All individuals who have provided informed consent, test positive by either HS-RDT or standard RDT, are ≥18 months old, are not pregnant or breastfeeding, and who do not have symptoms associated with severe malaria or another severe illness, will be offered an age-appropriate course of AL (age-specific blister packages) and SLD-PQ according to national treatment guidelines.
Study: NCT00645021
Drug: CP-945,598
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administration of CP-945,598 in subjects with mild hepatic function
Study: NCT00645021
Drug: CP-945,598
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administration of CP-945,598 in subjects with moderate hepatic function
Study: NCT00645021
Drug: CP-945,598
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administration of CP-945,598 in subjects with normal hepatic function
Study: NCT01559675
Drug: Hydrocortisone High Dose
Normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Patients receive Hydrocortisone 100 mg at surgical incision followed by 100mg IV every 8 hours for the first 24 hours, followed by 75 mg IV every 8 hours for 24 hours, followed by 50 mg IV every 8 hours for 24 hours, followed by 50 mg IV every 12 hours, followed by Prednisone 20 mg orally when oral diet is resumed
Study: NCT01559675
Drug: Hydrocortisone Low Dose
Normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 1/3 IV equivalent dose (IVED) (hydrocortisone equivalent of the patient's preoperative steroid dose) at surgical incision, followed by 1/3 IVED for 24 hours, Patients subsequently treated with 1/4 IVED every 8 hours starting Postoperative day (POD 1), followed by 1/6 IVED every 8 hours on POD 2 and every 12 hours starting POD 3. On POD 4 or when the patient was tolerating a regular diet, oral prednisone equal to the most recent IV hydrocortisone dose resumed
Study: NCT00007982
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00195533
Drug: glycopeptide
Normalized name: Glycopeptide
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00713544
Drug: AZD5672
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg oral, once daily
Study: NCT00713544
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo, oral, once daily
Study: NCT00713544
Drug: AZD5672
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg oral, once daily
Study: NCT00713544
Drug: AZD5672
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg oral, once daily
Study: NCT00713544
Drug: AZD5672
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg oral, once daily
Study: NCT00334243
Drug: Microflare protocol for IVF
Normalized name: Olay Professional Acne Protocol
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00334243
Drug: Demi-halt protocol for IVF
Normalized name: chlorpheniramine maleate / codeine phosphate / phenylephrine hydrochloride / potassium iodide Oral Solution [Demi-Cof]
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02444013
Drug: Folic acid
Normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02444013
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01510158
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablets, Placebo qd
Study: NCT04698603
Drug: 5 Methoxy N,N Dimethyltryptamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: GH001 administered via inhalation
Study: NCT03338218
Drug: Volulyte 6%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solution for infusion
Study: NCT03338218
Drug: Ionolyte
Normalized name: Isolyte H
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solution for infusion
Study: NCT00995709
Drug: AIN457
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00299416
Drug: Caffeinol
Normalized name: Caffeine
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Infusion of caffeinol (9mg/kg caffeine + 0.4g/kg ethanol) over 2 hours.
Study: NCT02397538
Drug: Rosuvastatin
Normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00995709
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00049504
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT00736593
Drug: Nexagon™ or Nexagon™ vehicle
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01199809
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: multiple doses
Study: NCT01199809
Drug: RO5310074
Approvals — FDA: no, EMA: no, PMDA: no
Description: multiple ascending doses
Study: NCT01969695
Drug: ABT-199
Normalized name: ABT-925
Approvals — FDA: no, EMA: no, PMDA: no
Description: ABT-199 continuous once daily dosing
Study: NCT01912196
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02233972
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00615459
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo to indacaterol (150 or 300 μg) delivered via SDDPI. The placebo for blinding tiotropium was delivered via the tiotropium manufacturer's proprietary inhalation device (HandiHaler®)
Study: NCT03994146
Drug: Remifentanil
Normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Syringe containing 40 ml of Remifentanil 50 µg/ml for intravenous administration.~In order to maintain double blinding two identical syringes, prepared by pharmacy according to randomisation, will be simultaneously infused. One of the syringes will be abruptly stopped at the end of the operation whilst the other is tapered by stepwise decreases in infusion rate prior to the end of surgery.
Study: NCT02866929
Drug: Mucograft
Approvals — FDA: no, EMA: no, PMDA: no
Description: Porcine naturally cross-linked collagen matrix
Study: NCT01837641
Drug: Placebo-IV
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered IV
Study: NCT01896661
Drug: Diuretics
Normalized name: DIURETICS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorthalidone plus amiloride 25 and 5 mg daily, taking in the morning
Study: NCT01896661
Drug: Calcium Channel Blockers
Normalized name: CALCIUM CHANNEL BLOCKERS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amlodipine 10 mg daily, taking in the morning
Study: NCT04812860
Drug: HR18042
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet, Dosing frequency: once daily, Route of administration: oral
Study: NCT01764555
Drug: acetaminophen 2 g
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02150447
Drug: Proton pump inhibitor
Normalized name: Proton pump inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lansoprazole 30 mg, daily
Study: NCT02150447
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, daily
Study: NCT04812860
Drug: HR18042
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet,Dosing frequency: once daily, Route of administration: oral
Study: NCT04812860
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet,Dosing frequency: once daily, Route of administration: oral
Study: NCT00535002
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00123123
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01652339
Drug: Exforge tab. 10/160mg
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01652339
Drug: Lodivixx tab. 5/160mg
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01740414
Drug: MN-166 (50 mg) First
Normalized name: Mn 2+
Approvals — FDA: no, EMA: no, PMDA: no
Description: In this arm of the study participants were first maintained on 50 mg MN-166 BID for approximately 14 days, and were then switched onto placebo maintenance. The subjective and analgesic effects of Oxycodone (0 mg, 15 mg and 30 mg) were tested under each of the two maintenance conditions (Placebo \& MN-166).
Study: NCT01740414
Drug: Placebo First
Approvals — FDA: no, EMA: no, PMDA: no
Description: This arm of the study participants were first maintained on placebo for approximately 14 days, and were then switched onto 50mg MN-166 BID maintenance. . The subjective and analgesic effects of Oxycodone (0 mg, 15 mg and 30 mg) were tested under each of the two maintenance conditions (Placebo \& MN-166).
Study: NCT04475120
Drug: SOC therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral administration
Study: NCT00536237
Drug: Comparator: placebo (unspecified) / Duration of Treatment: 17 Weeks
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03698227
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: iv infusion
Study: NCT02713945
Drug: Simvastatin
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Experimental drug administrated orally
Study: NCT02713945
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment for the control group
Study: NCT00880490
Drug: Inhaled PT005
Approvals — FDA: no, EMA: no, PMDA: no
Description: single dose, inhaled
Study: NCT00880490
Drug: Inhaled placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: single dose, inhaled
Study: NCT01641081
Drug: Foradil Aerolizer, High Dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Foradil Aerolizer 24 micrograms, twice per day for 14 days
Study: NCT01641081
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo in the Pressair for 14 days
Study: NCT02753426
Drug: Doxycycline
Normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Doxycycline 20mg capsule by mouth, twice a day for 30 days.
Study: NCT03538054
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 capsule, by mouth, twice daily every 12 hours.
Study: NCT02753426
Drug: Placebo (for Doxycycline)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inactive pill manufactured to mimic Doxycycline 20mg. Capsule by mouth, twice a for 30 days.
Study: NCT02759029
Drug: eradication of Helicobacter pylori
Normalized name: Combinations for eradication of Helicobacter pylori
Approvals — FDA: no, EMA: no, PMDA: no
Description: clarithromycin-based triple therapy Pantoloc 40mg, PO, BID, 1wk Amoxacillin 1g, PO, BID, 1wk Clarithromycin 500mg, PO, BID, 1wk~* concomitant therapy group Pantoloc 40mg, PO, BID, 1wk Amoxacillin 1g, PO, BID, 1wk Clarithromycin 500mg, PO, BID, 1wk Metronidazole 500mg, PO, BID, 1wk~* bismuth based quadraple therapy Pantoloc 40mg, PO, BID, 1wk Bismuth, 300mg, PO, QID, 1wk Tetracycline, 500mg, PO, QID, 1wk Metronidazole, 500mg, PO, TID, 1wk~* levofloxacine based triple therapy Pantoloc 40mg, PO, BID, 1wk Amoxacillin 1g, PO, BID, 1wk Levofloxacin 500mg, PO, QD, 1wk
Study: NCT00778310
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The collaborator (Ortho-McNiel Janssen Scientific Affairs, LLC) will provide capsules of placebo that are made to appear similar to Concerta capsules. The subject will be administered placebo the morning of the scan.
Study: NCT02757885
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cyclophosphamide is part of the bone marrow transplant preparative regimen. Cyclophosphamide will be administered on days -6 and -5 prior to bone marrow infusion at a dose of 14.5 mg/kg intravenously (IV) infused over 1-2 hours.~Post bone marrow infusion cyclophosphamide will be infused on days +3 (between 60 and 72 hours post marrow infusion) and +4 (approximately 24 hours after day +3 dose) at a dose of 50 mg/kg IV infused over 1-2 hours.~For participants weighing more than 125% of their ideal body weight, dosing will be based on adjusted ideal body weight.
Study: NCT00701246
Drug: folic acid
Normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00701246
Drug: placebo (folic acid)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00194727
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 825 mg/m2 twice a day; days 1 - 14 of each 3 week cycle. Treatment continues until disease progression, excessive toxicity or other reason to remove patient from protocol therapy.
Study: NCT01345188
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000 mg placebo orally once daily titrated as tolerated after 1 week up to taking 1000 mg twice daily.
Study: NCT04255589
Drug: Artemisia Herb 95% Ethanol Soft Ext.(20→1) 60mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Artemisiae argyi folium 95% ethanol ext.(20→1) 60mg Tab.
Study: NCT04255589
Drug: Placebo of the CKD-495 75mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo of the CKD-495 75mg Tab.
Study: NCT01801930
Drug: OCV-103 and OCV-104
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.3 mg of each
Study: NCT01801930
Drug: OCV-103 and OCV-104
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg of each
Study: NCT01801930
Drug: OCV-103 and OCV-104
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 mg of each
Study: NCT01801930
Drug: OCV-103 and OCV-104
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 mg of each
Study: NCT02909751
Drug: Cyclophosphamide 600 mg/m2 iv
Approvals — FDA: no, EMA: no, PMDA: no
Description: Max. 3 months
Study: NCT04255589
Drug: Placebo of Artemisia Herb 95% Ethanol Soft Ext.(20→1) 60mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo of Artemisia Herb 95% Ethanol Soft Ext.(20→1) 60mg Tab.
Study: NCT02411942
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (vehicle of the test product) applied to the entire face once daily for 84 consecutive days
Study: NCT00828672
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 825 mg/m2 ; 25 days - 5days per week, concurrent with radiotherapy
Study: NCT01849406
Drug: Nasal spray Normal Saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: one week therapy of nasal normal saline twice per day
Study: NCT00083525
Drug: WX-UK1 in combination with Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT04444466
Drug: UCB8600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Study participants will receive UCB8600 in a pre-specified sequence during the Treatment Period.
Study: NCT03699904
Drug: Placebo capsules (containing Avicel blend)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will self-administer two matching placebo capsules (containing Avicel blend) three times daily for 8 weeks.
Study: NCT02392468
Drug: Placebo matching BI 409306 25 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Film-coated tablet
Study: NCT01434849
Drug: Control (placebo) group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aqueous placebo, 1-2 drops to cover the hemangioma, twice daily
Study: NCT00651885
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT03095508
Drug: ANTI-ANGIN® FORMULA, topical metered spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0,12 mg + 0,24 mg (LLC Valeant, Russia) administered as one to two consecutive presses on the actuator button, up to 6 times per day, , for a maximum 5 days or until full illness resolution
Study: NCT02468141
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT00029380
Drug: Sangstat
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00029380
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02219490
Drug: ABT-450/r/ABT-267
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet for oral use
Study: NCT02219490
Drug: ABT-333
Normalized name: ABT-925
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet for oral use
Study: NCT00679380
Drug: Entocort EC® 3 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 9 mg/day, 3 mg tablets
Study: NCT00679380
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT02376478
Drug: TNF-alpha inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Description: therapy for at least 6 months
Study: NCT02376478
Drug: Purine/folic acid analogues
Approvals — FDA: no, EMA: no, PMDA: no
Description: therapy for at least 6 months
Study: NCT02116361
Drug: Normal Saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (normal saline) injected into protocol-specified areas on Day 1.
Study: NCT04021706
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo is a inert substance
Study: NCT02332798
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered as specified in the treatment arm
Study: NCT00789724
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.67 ml of NaCl 0.9% subcutaneously daily for 14 days
Study: NCT00595868
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: same as Varenicline arm
Study: NCT01855841
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: A single perfusion of 100mL of NaCl 0.9% administered as soon as possible after the end of the ERCP followed by 100mL of NaCL 0.9% to flush the vein
Study: NCT03199144
Drug: Chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 cycles of Gemzar-Abraxane
Study: NCT01756638
Drug: Prednisolone
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prednisolone will be administered orally as 5 mg tablets twice daily for 28-daily dosing cycle which will be continued until disease progression or unacceptable toxicity.
Study: NCT04268303
Drug: Placebo Film
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo Film for BXCL501
Study: NCT00805818
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium Chloride 0.9% Injection